miR-520f-3p blocks MNNG-induced gastric precancerous lesions via the KLF7/NF κB pathway
This study aimed to investigate the effect of miR-520f-3p in the N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)-induced GPL model and to elucidate the role of its downstream target gene Kruppel-like factor 7 (KLF7) in it. The experimental results showed that miR-520f-3p expression was down-regulated in the MNNG-induced GES-1 cell model, and overexpression of miR-520f-3p reversed the effects of MNNG on cell migration, invasion and epithelial-mesenchymal transition (EMT) -related protein expression. Meanwhile, overexpression of KLF7 attenuated the effect of miR-520f-3p on GPL. In a mouse GPL model, it was observed that MNNG eli...
Source: Toxicology Letters - January 6, 2024 Category: Toxicology Authors: Wei Jiang Wei Lu Jun Liu Haixia Ren Xuequn Zhao Wenjie Yang Source Type: research
AChE reactivation in Precision-cut lung slices following organophosphorus compound poisoning
In this study, the AChE activity was determined in intact PCLS for the first time. Since the current standard therapy for OP poisoning (atropine + oxime + benzodiazepine) lacks efficiency, reliable models to study novel therapeutic substances are needed. Models should depict pathophysiological mechanisms and help to evaluate the beneficial effects of new therapeutics. Here PCLS were exposed to three organophosphorus nerve agents (OPNAs): sarin (GB), cyclosarin (GF), and VX. They were then treated with three reactivators: HI-6, obidoxime (OBI), and a non-oxime (NOX-6). The endpoints investigated in this study were the AChE ...
Source: Toxicology Letters - December 31, 2023 Category: Toxicology Authors: Fee G ölitz Julia Herbert Franz Worek Timo Wille Source Type: research
AChE reactivation in Precision-cut lung slices following organophosphorus compound poisoning
In this study, the AChE activity was determined in intact PCLS for the first time. Since the current standard therapy for OP poisoning (atropine + oxime + benzodiazepine) lacks efficiency, reliable models to study novel therapeutic substances are needed. Models should depict pathophysiological mechanisms and help to evaluate the beneficial effects of new therapeutics. Here PCLS were exposed to three organophosphorus nerve agents (OPNAs): sarin (GB), cyclosarin (GF), and VX. They were then treated with three reactivators: HI-6, obidoxime (OBI), and a non-oxime (NOX-6). The endpoints investigated in this study were the AChE ...
Source: Toxicology Letters - December 31, 2023 Category: Toxicology Authors: Fee G ölitz Julia Herbert Franz Worek Timo Wille Source Type: research
AChE reactivation in Precision-cut lung slices following organophosphorus compound poisoning
In this study, the AChE activity was determined in intact PCLS for the first time. Since the current standard therapy for OP poisoning (atropine + oxime + benzodiazepine) lacks efficiency, reliable models to study novel therapeutic substances are needed. Models should depict pathophysiological mechanisms and help to evaluate the beneficial effects of new therapeutics. Here PCLS were exposed to three organophosphorus nerve agents (OPNAs): sarin (GB), cyclosarin (GF), and VX. They were then treated with three reactivators: HI-6, obidoxime (OBI), and a non-oxime (NOX-6). The endpoints investigated in this study were the AChE ...
Source: Toxicology Letters - December 31, 2023 Category: Toxicology Authors: Fee G ölitz Julia Herbert Franz Worek Timo Wille Source Type: research
AChE reactivation in Precision-cut lung slices following organophosphorus compound poisoning
In this study, the AChE activity was determined in intact PCLS for the first time. Since the current standard therapy for OP poisoning (atropine + oxime + benzodiazepine) lacks efficiency, reliable models to study novel therapeutic substances are needed. Models should depict pathophysiological mechanisms and help to evaluate the beneficial effects of new therapeutics. Here PCLS were exposed to three organophosphorus nerve agents (OPNAs): sarin (GB), cyclosarin (GF), and VX. They were then treated with three reactivators: HI-6, obidoxime (OBI), and a non-oxime (NOX-6). The endpoints investigated in this study were the AChE ...
Source: Toxicology Letters - December 31, 2023 Category: Toxicology Authors: Fee G ölitz Julia Herbert Franz Worek Timo Wille Source Type: research
AChE reactivation in Precision-cut lung slices following organophosphorus compound poisoning
In this study, the AChE activity was determined in intact PCLS for the first time. Since the current standard therapy for OP poisoning (atropine + oxime + benzodiazepine) lacks efficiency, reliable models to study novel therapeutic substances are needed. Models should depict pathophysiological mechanisms and help to evaluate the beneficial effects of new therapeutics. Here PCLS were exposed to three organophosphorus nerve agents (OPNAs): sarin (GB), cyclosarin (GF), and VX. They were then treated with three reactivators: HI-6, obidoxime (OBI), and a non-oxime (NOX-6). The endpoints investigated in this study were the AChE ...
Source: Toxicology Letters - December 31, 2023 Category: Toxicology Authors: Fee G ölitz Julia Herbert Franz Worek Timo Wille Source Type: research
Regenerative and progressing lesions in lungs and lung-associated lymph nodes from fourteen 90-day inhalation studies with chemically different particulate materials
Toxicol Lett. 2023 Dec 28:S0378-4274(23)01118-9. doi: 10.1016/j.toxlet.2023.12.011. Online ahead of print.ABSTRACTRat lungs and lung-associated lymph nodes from 14 inhalation studies with chemically different particulate materials were histopathologically re-evaluated, and the bronchoalveolar lavage fluid (BALF) data and lung burden analyses were compared. All investigated substances caused similar lesions. For most substances, 1mg/m3 of respirable particulate matter was established as the borderline for adverse morphological changes after the 90-day exposure period, confirmed by the increase in polymorphonuclear neutrophi...
Source: Toxicology Letters - December 30, 2023 Category: Toxicology Authors: Klaus Weber Gustav Bruer Nils Krueger Tobias B Schuster Otto Creutzenberg Dirk Schaudien Source Type: research
In vitro Permeation of Nicotine and Tobacco Specific Nitrosamines from Smokeless Tobacco Product Extracts in a 3D Buccal Tissue Model
Toxicol Lett. 2023 Dec 22:S0378-4274(23)01120-7. doi: 10.1016/j.toxlet.2023.12.013. Online ahead of print.ABSTRACTTobacco product use is a risk factor in the development of oral cancer, although epidemiology studies show this risk is far less with smokeless tobacco product use than cigarette smoking. While smokeless tobacco contains harmful and potentially harmful constituents (HPHCs), the oral permeation of HPHCs in oral tobacco products is not completely understood. To improve the understanding, three different extract concentrations of the CORESTA reference products (CRP) for snus (CRP1.1) and moist snuff (CRP2.1) were ...
Source: Toxicology Letters - December 24, 2023 Category: Toxicology Authors: Brian M Keyser Hannah Flockton Randy A Weidman Rebecca Payne Jannell Rowe Kristen G Jordan Source Type: research
In vitro Permeation of Nicotine and Tobacco Specific Nitrosamines from Smokeless Tobacco Product Extracts in a 3D Buccal Tissue Model
Toxicol Lett. 2023 Dec 22:S0378-4274(23)01120-7. doi: 10.1016/j.toxlet.2023.12.013. Online ahead of print.ABSTRACTTobacco product use is a risk factor in the development of oral cancer, although epidemiology studies show this risk is far less with smokeless tobacco product use than cigarette smoking. While smokeless tobacco contains harmful and potentially harmful constituents (HPHCs), the oral permeation of HPHCs in oral tobacco products is not completely understood. To improve the understanding, three different extract concentrations of the CORESTA reference products (CRP) for snus (CRP1.1) and moist snuff (CRP2.1) were ...
Source: Toxicology Letters - December 24, 2023 Category: Toxicology Authors: Brian M Keyser Hannah Flockton Randy A Weidman Rebecca Payne Jannell Rowe Kristen G Jordan Source Type: research
In vitro Permeation of Nicotine and Tobacco Specific Nitrosamines from Smokeless Tobacco Product Extracts in a 3D Buccal Tissue Model
Toxicol Lett. 2023 Dec 22:S0378-4274(23)01120-7. doi: 10.1016/j.toxlet.2023.12.013. Online ahead of print.ABSTRACTTobacco product use is a risk factor in the development of oral cancer, although epidemiology studies show this risk is far less with smokeless tobacco product use than cigarette smoking. While smokeless tobacco contains harmful and potentially harmful constituents (HPHCs), the oral permeation of HPHCs in oral tobacco products is not completely understood. To improve the understanding, three different extract concentrations of the CORESTA reference products (CRP) for snus (CRP1.1) and moist snuff (CRP2.1) were ...
Source: Toxicology Letters - December 24, 2023 Category: Toxicology Authors: Brian M Keyser Hannah Flockton Randy A Weidman Rebecca Payne Jannell Rowe Kristen G Jordan Source Type: research
In vitro Permeation of Nicotine and Tobacco Specific Nitrosamines from Smokeless Tobacco Product Extracts in a 3D Buccal Tissue Model
Toxicol Lett. 2023 Dec 22:S0378-4274(23)01120-7. doi: 10.1016/j.toxlet.2023.12.013. Online ahead of print.ABSTRACTTobacco product use is a risk factor in the development of oral cancer, although epidemiology studies show this risk is far less with smokeless tobacco product use than cigarette smoking. While smokeless tobacco contains harmful and potentially harmful constituents (HPHCs), the oral permeation of HPHCs in oral tobacco products is not completely understood. To improve the understanding, three different extract concentrations of the CORESTA reference products (CRP) for snus (CRP1.1) and moist snuff (CRP2.1) were ...
Source: Toxicology Letters - December 24, 2023 Category: Toxicology Authors: Brian M Keyser Hannah Flockton Randy A Weidman Rebecca Payne Jannell Rowe Kristen G Jordan Source Type: research
In vitro Permeation of Nicotine and Tobacco Specific Nitrosamines from Smokeless Tobacco Product Extracts in a 3D Buccal Tissue Model
Toxicol Lett. 2023 Dec 22:S0378-4274(23)01120-7. doi: 10.1016/j.toxlet.2023.12.013. Online ahead of print.ABSTRACTTobacco product use is a risk factor in the development of oral cancer, although epidemiology studies show this risk is far less with smokeless tobacco product use than cigarette smoking. While smokeless tobacco contains harmful and potentially harmful constituents (HPHCs), the oral permeation of HPHCs in oral tobacco products is not completely understood. To improve the understanding, three different extract concentrations of the CORESTA reference products (CRP) for snus (CRP1.1) and moist snuff (CRP2.1) were ...
Source: Toxicology Letters - December 24, 2023 Category: Toxicology Authors: Brian M Keyser Hannah Flockton Randy A Weidman Rebecca Payne Jannell Rowe Kristen G Jordan Source Type: research
In vitro Permeation of Nicotine and Tobacco Specific Nitrosamines from Smokeless Tobacco Product Extracts in a 3D Buccal Tissue Model
Toxicol Lett. 2023 Dec 22:S0378-4274(23)01120-7. doi: 10.1016/j.toxlet.2023.12.013. Online ahead of print.ABSTRACTTobacco product use is a risk factor in the development of oral cancer, although epidemiology studies show this risk is far less with smokeless tobacco product use than cigarette smoking. While smokeless tobacco contains harmful and potentially harmful constituents (HPHCs), the oral permeation of HPHCs in oral tobacco products is not completely understood. To improve the understanding, three different extract concentrations of the CORESTA reference products (CRP) for snus (CRP1.1) and moist snuff (CRP2.1) were ...
Source: Toxicology Letters - December 24, 2023 Category: Toxicology Authors: Brian M Keyser Hannah Flockton Randy A Weidman Rebecca Payne Jannell Rowe Kristen G Jordan Source Type: research
In vitro Permeation of Nicotine and Tobacco Specific Nitrosamines from Smokeless Tobacco Product Extracts in a 3D Buccal Tissue Model
Toxicol Lett. 2023 Dec 22:S0378-4274(23)01120-7. doi: 10.1016/j.toxlet.2023.12.013. Online ahead of print.ABSTRACTTobacco product use is a risk factor in the development of oral cancer, although epidemiology studies show this risk is far less with smokeless tobacco product use than cigarette smoking. While smokeless tobacco contains harmful and potentially harmful constituents (HPHCs), the oral permeation of HPHCs in oral tobacco products is not completely understood. To improve the understanding, three different extract concentrations of the CORESTA reference products (CRP) for snus (CRP1.1) and moist snuff (CRP2.1) were ...
Source: Toxicology Letters - December 24, 2023 Category: Toxicology Authors: Brian M Keyser Hannah Flockton Randy A Weidman Rebecca Payne Jannell Rowe Kristen G Jordan Source Type: research
Acrolein suppresses anticancer drug-induced toxicity mediated by activating claudin-1 and Nrf2 axis in a spheroid model of human lung squamous cell carcinoma cells
In this study, we found that acrolein increases the mRNA and protein levels of CLDN1 in RERF-LC-AI cells derived from human lung squamous cell carcinoma (SCC). Acrolein increased the p-extracellular signal-regulated kinase (ERK) 1/2 levels without affecting the p-Akt level. The acrolein-induced elevation of CLDN1 expression was attenuated by U0126, a mitogen-activated protein kinase kinas (MEK) inhibitor. These results indicate that the activation of MEK/ERK pathway is involved in the acrolein-induced elevation of CLDN1 expression. In a spheroid model, acrolein suppressed the accumulation and toxicity of doxorubicin (DXR),...
Source: Toxicology Letters - December 23, 2023 Category: Toxicology Authors: Hiroaki Eguchi Yaqing Yu Toshiyuki Matsunaga Yuta Yoshino Akira Ikari Source Type: research
